Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan - Summary - MDSpire
Advertisement
Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan
To evaluate the incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with Tixagevimab-Cilgavimab (Tix/Cil) in Japan, highlighting its significance for immunocompromised populations.
Key Findings:
The incidence of breakthrough COVID-19 was 7.5% (18 of 257 patients), indicating a significant occurrence in this vulnerable population.
Cumulative infection rates were 4.3% at 30 days and 8.2% at 100 days post-Tix/Cil administration, suggesting a need for ongoing monitoring.
COVID-19 severity included mild (11), moderate (2), and severe (4) cases, with no deaths reported, highlighting the efficacy of Tix/Cil in preventing severe outcomes.
Interpretation:
The incidence of breakthrough COVID-19 in this cohort is comparable to previous studies, suggesting Tix/Cil retains efficacy against severe disease in immunocompromised patients, which is crucial for treatment planning.
Limitations:
Retrospective design without a control group limits the evaluation of Tix/Cil's absolute efficacy, necessitating caution in interpretation.
Statistical analysis of patient characteristics related to breakthrough infections was limited due to sample size, which may affect the robustness of findings.
Conclusion:
This study provides real-world data on breakthrough COVID-19 incidence in immunocompromised patients in Japan, indicating the preserved efficacy of Tix/Cil against severe disease, which is vital for informing clinical practice.
